| Aug 6 |
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
|
| Aug 6 |
Dynavax Technologies: Q2 Earnings Snapshot
|
| Aug 6 |
Dynavax GAAP EPS of $0.08 beats by $0.02, revenue of $73.8M misses by $2.24M
|
| Aug 6 |
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Aug 5 |
Dynavax Q2 2024 Earnings Preview
|
| Jul 23 |
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
|
| Jun 28 |
Dynavax doses first subject in Phase I/II shingles vaccine trial
|
| Jun 27 |
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
|
| Jun 11 |
Dynavax, Bloomin' Brands, and Premier are the most shorted small-cap stock in May - Hazeltree report
|
| May 28 |
Dynavax to Present at Upcoming Investor Conferences
|
